New Delhi, October 17: Should we say this a good piece of news? The drug which is also termed as ‘female Viagra’ — Addyi — has hit the medical stores from Saturday onwards. But there is a twist. In order to get the drug, the patient needs to consult a registered doctor and get it prescribed in order to get it from medical stores. The new drug, Addyi, which aims to boost female libido can’t be taken with alcohol or certain other drugs, which might limit its use.Also Read - Sale of Condoms & Sex Toys Skyrocket As Indians Make the Most of Coronavirus Lockdown

The new invention of Addyi acts on brain chemicals associated with desire, commonly known as Hypoactive Sexual Desire Disorder or HSDD. While the previous Viagra and other men’s erectile dysfunction drugs work by increasing blood flow to the genitals. As per to the reports, the new drug will come with a statuary bold warning label stating the risks of fainting if combined with alcohol or certain other medications. The reason behind the warning is, earlier the use of drug led to issues like nausea, fatigue and dizziness among the takers. (ALSO READ: No decision to allow sale of medicine using internet: Union Health Minister J P Nadda) Also Read - Sheep in Ireland Become Sexually Overactive After Drinking Water Contaminated With Viagra

As the new drug entered the market on Saturday, predictions are there that with the launch of Addyi, new entrants will get an opportunity to explore the new business area and get a gateway. Speaking to the Associate Press, psychology professor at Emory University Kim Wallen said, “This is the first time that a drug, for either men or women, has been approved strictly to increase sexual desire. That legitimises many other drugs that are in development.” Also Read - Procter & Gamble Q1 net up 24.7 pc to Rs 144.11 crore

If believed by the reports, the journey for Addyi was not an easy ride. Back in 1990, companies like Pfizer, Bayer and Procter & Gamble all did a research and then discarded it for its side-effects. Addyi was first developed by German conglomerate Boehringer Ingelheim, but was sold to Sprout Pharmaceuticals after the Food and Drug Administration (FDA) in United States rejected the medication due to the complications it involved. For Sprout it took four years to it approved from the FDA. Now with the launch of the new drug, it has become a wait and watch scene on how much successful it would be. (ALSO READ: Sexual transmission of Ebola virus in Liberia confirmed)